EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2025.06.20
CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia®
2025.06.17
CanSinoBIO Launches First-in-Class Three-Component LNP Delivery System: Enhances T Cell Response and Safety, Surpassing Industry Patent Barriers
2025.05.15
CanSinoBIO Obtained Approval for Clinical Trials of Inhaled TB Vaccine in Indonesia
2025.03.26
SPIMACO and CanSinoBIO Sign an Agreement to Localise and Market the MCV4 Vaccine in Saudi Arabia and MENA
2025.03.21
Professor Adrian V. S. Hill FRS from Oxford University Visits CanSinoBIO, Highlights Vaccine Innovations
2025.02.24
CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine
2025.02.07
CanSinoBIO Announces Priority Review Status for DTcP Infant
2025.02.06
CanSinoBIO Obtained Halal Decree of Menhycia® in Indonesia
2025.02.06
CanSinoBIO Received Acceptance of New Drug Application for its Tetanus Vaccine
2024.10.09
CanSinoBIO Secures Further Grant Funding
1234568